Moderna just delivered a stunning comeback. The biotech giant recorded +631% quarter-over-quarter revenue growth in Q4 2025, claiming the top spot among all S&P 500 companies.
The Revenue Surge
Revenue exploded from $137M in Q3 to $1,002M in Q4 2025. This marks Moderna's second consecutive quarter of growth. The gap to the competition is massive—runner-up Bunge Global (BG) posted just +73.5% QoQ growth.
Rank | Company | Q4 Revenue QoQ |
|---|---|---|
1 | MRNA | +631.39% |
2 | BG | +73.51% |
3 | DECK | +48.34% |
4 | FSLR | +45.36% |
5 | APO | +44.16% |
Profit Recovery: #1 in Healthcare
Beyond revenue, Moderna leads the Healthcare sector in profit improvement. Net income improved from -$825M (Q3) to -$200M (Q4), a +71.33% QoQ gain. Net margin recovered dramatically from -602% to -20%.
While still unprofitable, this trajectory stands out. Among 58 Healthcare stocks in the S&P 500, MRNA ranks #1 in profit QoQ improvement. Danaher (DHR) trails at +51.8%, followed by Centene (CNC) at +47.6%.
Healthcare Rank | Company | Profit QoQ |
|---|---|---|
1 | MRNA | +71.33% |
2 | DHR | +51.84% |
3 | CNC | +47.64% |
News Sentiment: Cautiously Optimistic
Based on Quatable's 30-day news analysis (5 articles), market sentiment toward MRNA leans positive. Key highlights from recent coverage:
Benzinga (Jan 2026): "Moderna rallied 14% on bullish forecasts" amid mixed earnings season. The stock outperformed while JPMorgan and Delta declined.
The Motley Fool: Named MRNA among "Top 5 Stocks to Buy in Early 2026," describing it as a "biotech recovery story with pipeline expansion." The analyst noted MRNA represents a higher-risk growth opportunity compared to proven earners like Amazon and Apple.
GlobeNewswire: The nanobiotechnology market is projected to reach $420B by 2034, highlighting tailwinds for mRNA technology platforms.
The Bigger Picture
Context matters. Moderna's annual revenue collapsed from $18.9B (2022) to $3.2B (2024)—an 83% decline as pandemic vaccine demand faded. This Q4 surge signals a potential inflection point.
Operating losses narrowed significantly: from -$907M (Q3) to -$260M (Q4). The company now shows two consecutive quarters of growth for the first time since the pandemic peak.
Investment Insight
Moderna's seasonal vaccine cycle drives this volatility. Q4 typically captures respiratory season demand for flu and COVID vaccines. The real test is whether momentum continues into 2026.
Current market cap sits at $15.5B. Watch for pipeline catalysts in RSV vaccines, cancer therapeutics, and rare disease treatments. The mRNA platform's versatility could unlock new revenue streams beyond COVID.
Data source: Quatable S&P 500 Analysis (Updated Jan 14, 2026)
Quatable LINK:
MRNA
→